Investors sold shares of Eli Lilly and Co. (NYSE:LLY) on strength during trading hours on Monday after an insider sold shares in the company. $66.06 million flowed into the stock on the tick-up and $110.85 million flowed out of the stock on the tick-down, for a money net flow of $44.79 million out of the stock. Of all stocks tracked, Eli Lilly and had the 10th highest net out-flow for the day. Eli Lilly and traded up $0.97 for the day and closed at $83.06Specifically, insider Donald A. Zakrowski sold 1,213 shares of Eli Lilly and stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the transaction, the insider now directly owns 1,300 shares in the company, valued at approximately $108,108. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Tuesday, July 12th. The shares were sold at an average price of $79.54, for a total value of $16,703,400.00. Following the transaction, the insider now owns 126,220,804 shares in the company, valued at $10,039,602,750.16. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Several equities analysts have recently issued reports on the company. BMO Capital Markets reiterated a “buy” rating and set a $94.00 price target on shares of Eli Lilly and in a research report on Monday, October 3rd. JPMorgan Chase & Co. upgraded Eli Lilly and from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $92.00 to $95.00 in a research report on Thursday, September 8th. Leerink Swann reiterated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research report on Sunday. Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. Finally, Jefferies Group restated a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a report on Wednesday, September 14th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $97.06.
The firm has a 50 day moving average price of $79.44 and a 200 day moving average price of $77.49. The company has a market capitalization of $87.85 billion, a P/E ratio of 35.80 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The business earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter in the prior year, the company earned $0.90 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Equities analysts expect that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. RNC Capital Management LLC boosted its position in Eli Lilly and by 42.4% in the second quarter. RNC Capital Management LLC now owns 410,784 shares of the company’s stock worth $32,349,000 after buying an additional 122,237 shares during the period. Private Capital Advisors Inc. purchased a new position in Eli Lilly and during the second quarter worth about $28,535,000. AMP Capital Investors Ltd boosted its position in Eli Lilly and by 6.9% in the first quarter. AMP Capital Investors Ltd now owns 512,346 shares of the company’s stock worth $36,776,000 after buying an additional 32,848 shares during the period. Country Trust Bank boosted its position in Eli Lilly and by 0.4% in the second quarter. Country Trust Bank now owns 252,356 shares of the company’s stock worth $19,873,000 after buying an additional 909 shares during the period. Finally, FineMark National Bank & Trust boosted its position in Eli Lilly and by 0.5% in the second quarter. FineMark National Bank & Trust now owns 27,787 shares of the company’s stock worth $2,189,000 after buying an additional 138 shares during the period. Institutional investors and hedge funds own 74.96% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.